You are here

Article info

Article menu
Download PDFPDF
Letter
A pilot study of tofacitinib for refractory Behçet’s syndrome

Authors

  • Jinjing Liu Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Yunxia Hou Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China PubMed articlesGoogle scholar articles
  • Luxi Sun Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Chaoran Li Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Lu Li Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Yan Zhao Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Xiaofeng Zeng Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Fengchun Zhang Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  • Wenjie Zheng Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; wenjzheng{at}gmail.com
View Full Text

Citation

Liu J, Hou Y, Sun L, et al
A pilot study of tofacitinib for refractory Behçet’s syndrome
Annals of the Rheumatic Diseases 2020;79:1517-1520.

Publication history

  • Received March 7, 2020
  • Revised May 9, 2020
  • Accepted May 12, 2020
  • First published May 27, 2020.
Online issue publication 
May 12, 2021

Article Versions

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.